Trijardy XR

Indicated For

type 2 diabetes

About This Medication

# Boehringer Cares Patient Assistance Program Patient Guide: How to Get Trijardy XR at Low or No Cost Trijardy XR (empagliflozin, linagliptin, and metformin extended-release tablets) is a prescription medication used to improve blood sugar control in adults with **type 2 diabetes** when diet and exercise alone are not enough. The **Boehringer Cares Patient Assistance Program**, offered by Boehringer Ingelheim through the nonprofit Boehringer Ingelheim Cares Foundation, provides this and other eligible medications **free of charge** to qualifying uninsured or underinsured patients in the United States.[1][2][7] ## About Trijardy XR **Trijardy XR** combines three active ingredients: **empagliflozin** (an SGLT2 inhibitor that helps the kidneys remove excess sugar through urine), **linagliptin** (a DPP-4 inhibitor that increases insulin release and decreases sugar production in the liver), and **metformin** (a biguanide that reduces glucose production in the liver and improves insulin sensitivity). Taken once daily with a meal, it helps lower A1C levels and supports better glycemic control. Common side effects may include urinary tract infections, yeast infections, nausea, or dehydration risks—always discuss with your doctor. This program covers Trijardy XR for eligible patients struggling with costs.[1][2] ## Who Qualifies? To qualify for the **Boehringer Cares Patient Assistance Program**, you must meet these key criteria: - Be a resident of the **United States or a U.S. territory** (including Puerto Rico) with a physical address.[2][3] - Have a **valid prescription** for Trijardy XR from a U.S. healthcare provider.[1] - Meet **household income guidelines** set by BI Cares (specific dollar amounts not publicly listed; program verifies based on your details).[1][2] - Have **no health coverage, inadequate coverage** for the medication, or unaffordable out-of-pocket costs, with no access to other funding sources.[2][3][6] **Medicare Part D patients** may qualify if they face high costs, lack other coverage, and don't qualify for Low-Income Subsidy (LIS)—contact the program to confirm.[3][6] ## Income Eligibility Breakdown Exact income thresholds (e.g., as a percentage of the Federal Poverty Level) are **not publicly detailed** and vary by household size. BI Cares evaluates on a case-by-case basis, often requesting proof like IRS Form 1040 or pay stubs.[1][2] Here's a general overview based on program notes: | Household Size | Estimated Threshold | Notes | |---------------|---------------------|-------| | Individual | Meets BI guidelines | Proof required if selected; call for details | | Couple | Meets BI guidelines | Household income combined | | Family of 3 | Meets BI guidelines | Includes dependents | | Family of 4+ | Meets BI guidelines | Scaled by size; verify with program | **Tip**: Income is assessed annually or upon changes. Do not apply if your household income exceeds guidelines or you have adequate coverage.[2] ## Insurance Requirements The program targets those who **cannot afford Trijardy XR** due to: - **No prescription coverage** at all.[2] - **Underinsured**: Coverage exists but doesn't cover the drug or copays are too high.[1][3] - **Medicare/Medicaid**: Part D enrollees may qualify if costs are burdensome and no LIS denial letter is needed upfront (attach if available). Commercially insured patients can apply if out-of-pocket is unaffordable, but you agree not to seek reimbursement from insurers.[2][3][6] You must attest that BI Cares medication won't be reimbursed by any government or private payer.[2] ## Step-by-Step Application Process 1. **Discuss with Your Doctor**: Ensure you have a valid Trijardy XR prescription. Your healthcare provider (HCP) must complete **Sections 5 & 6** of the application, including original signature, confirming medical need.[2] 2. **Download the Form**: Get the official application from the Boehringer Ingelheim website: [application URL].[5] 3. **Complete Sections 1-4**: Fill in patient info (name, address, income details), insurance status, and sign. Note delivery ships to your address unless specified.[2] 4. **Gather Documents**: - Completed, signed application (Sections 1-6). - **Proof of income** if requested (e.g., tax returns, pay stubs—see Section 2).[2] - HCP-completed sections. - Optional: Medicare LIS denial letter.[2] 5. **Submit**: - **Fax**: 1-866-851-2827[3] - **Mail**: Boehringer Cares Patient Assistance Program, PO Box 99055, Jeffersontown, KY 40296[3] - Multiple methods available; follow form instructions.[4] 6. **Sign Authorizations**: Consent to share health/insurance info for verification and agree to updates.[2] **Pro Tip**: Services like Simplefill can assist with applications—call (877) 386-0206.[1] For help, contact 800-556-8317 (Mon-Fri, 8:30 AM–6:00 PM ET).[3] ## Timeline and Delivery Processing time varies; expect **several weeks** for review. Medication is **shipped free directly to your home** (or specified address). **Reauthorization is required** annually or upon changes in income/insurance—program notifies you.[2][3] Stay proactive to avoid gaps. ## Alternatives if Denied - **Other BI Programs**: Check Boehringer's site for copay cards or foundation grants if income slightly exceeds.[7] - **Simplefill or RxAssist**: They match you to similar programs.[1][6] - **State Assistance**: Medicaid, state pharmaceutical aid, or 340B clinics. - **Generic Options**: Discuss empagliflozin, linagliptin, or metformin alternatives with your doctor. - **NeedyMeds or PAN Foundation**: Broader diabetes grants. No biosimilars for Trijardy XR currently.[program details] ## Important Disclaimer This guide is for informational purposes only and based on publicly available data as of 2026. Eligibility, terms, and availability can change—**always verify directly with Boehringer Cares** at 800-556-8317 or their site. Not medical or legal advice; consult your healthcare provider. BI Cares reserves the right to independently verify info and deny based on criteria. Free product is not for resale; violations may lead to ineligibility.[2][7] (Word count: 1028)

Program information last verified: March 25, 2026